On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst. The company said it now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October, narrowing guidance that had previously pointed only to sometime in the fourth quarter. For a clinical-stage vaccine company with no approved product on the market, that single change is the headline. The two executives brought in alongside it suggest Vaxcyte believes it is close enough to a launch to need people who have done this before.
Hiring For The Next Stage
Luis Jodar, Ph.D. joins as Chief Medical Officer after 17 years at Pfizer, where he served as Chief Medical Officer for Vaccines and Infectious Diseases and helped lead the clinical development and medical affairs work behind Prevnar 13 and Prevnar 20, the pneumococcal vaccines that currently dominate the adult market VAX-31 is trying to enter. He also worked on Abrysvo, Comirnaty, and Paxlovid, and earlier in his career helped lead the Meningitis Vaccine Project at the World Health Organization, an effort that produced MenAfriVac and has since reached more than 400 million people across sub-Saharan Africa. He has authored roughly 200 publications and served as the industry representative on the FDA’s Vaccines and Related Biological Products Advisory Committee. In plain terms, Vaxcyte just hired one of the people who built the products it is trying to beat.
David McAvoy, J.D., arrives as Chief Legal Officer from Teva Pharmaceutical, where he ran a 235-person legal, compliance, and government affairs organization as Executive Vice President and Chief Legal Officer. Before Teva, he served as General Counsel of Endocyte through its $2.1 billion acquisition by Novartis, a deal that led to the launch of Pluvicto, and spent 27 years at Eli Lilly in senior legal roles, including General Counsel, International and FDA Senior Counsel, work that touched the development and launch of Prozac and Cialis. Vaxcyte is preparing a Biologics License Application for VAX-31, and McAvoy has already walked other companies through that exact process. Meanwhile, the OPUS-1 trial alone dosed 4,049 participants in a head-to-head comparison against Prevnar 20 and Capvaxive, the two standard-of-care vaccines, part of a broader Phase 3 program that has dosed 6,191 adults in total, roughly 3,500 of them with VAX-31. As of June 30, 2026, Vaxcyte held about $2.5 billion in cash, cash equivalents, and investments, enough to fund a BLA submission without tapping the market for cash.
One Trial Still Decides Everything
None of that leadership depth changes what OPUS-1 needs to show. The trial is measuring safety, tolerability, and immunogenicity against Prevnar 20 and Capvaxive, not a fresh efficacy claim of its own, so the near-term thesis rests on VAX-31 clearing a noninferiority bar against vaccines already entrenched with doctors and payers. Prevnar 20 comes from Pfizer, Jodar’s former employer, and Capvaxive comes from Merck, both companies with existing sales relationships that VAX-31 would still need to displace even after a clean readout.
Vaxcyte still has no approved product and no product revenue, which means both new executives are being paid to prepare for a market the company has not yet entered. The rest of the pipeline sits well behind OPUS-1. Data from the OPUS-2 and OPUS-3 trials, covering flu vaccine co-administration and prior-vaccination boosting, are not expected until the first half of 2027, and results from the VAX-31 infant Phase 2 study are guided to that same window. The Group A Strep candidate, VAX-A1, only dosed its first participant in June 2026 and is not expected to produce topline data until the second half of 2027. Even after the OPUS-1 readout, Vaxcyte still needs a manufacturing consistency study before it can file its BLA, one more step between now and any commercial launch.
Where The Smart Money Sits
Hedge fund ownership of Vaxcyte fell from 57 funds to 47 in the most recent quarter, pointing to some institutional trimming ahead of the OPUS-1 readout. Short interest sits at 10.14% of the float, solidly in double-digit territory, a sign of real skepticism rather than a handful of routine hedges. Fewer funds holding shares alongside heavy short interest is not the setup you would expect right before what management is framing as a de-risking event. That tension cuts both ways, since it could mean the market doubts the trial will go cleanly, or it could mean a clean readout forces a scramble to cover.
What The Next Six Weeks Decide
Vaxcyte used September 3 to do two things at once: build the leadership bench it will need if VAX-31 succeeds, and pull forward the date investors will find out whether it does. Jodar spent years building the vaccines VAX-31 is trying to unseat, and McAvoy has steered other biotechs through the exact BLA and launch process Vaxcyte hopes to enter next. Neither hire changes what the OPUS-1 data actually show when they arrive by the end of October, only how quickly the company can act on the result.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center